IL325355A - RNA inhibitor targeting huntingtin expression - Google Patents

RNA inhibitor targeting huntingtin expression

Info

Publication number
IL325355A
IL325355A IL325355A IL32535525A IL325355A IL 325355 A IL325355 A IL 325355A IL 325355 A IL325355 A IL 325355A IL 32535525 A IL32535525 A IL 32535525A IL 325355 A IL325355 A IL 325355A
Authority
IL
Israel
Prior art keywords
sequence
seq
raav
rna
polynucleotide
Prior art date
Application number
IL325355A
Other languages
English (en)
Hebrew (he)
Original Assignee
Spark Therapeutics Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc, Genentech Inc filed Critical Spark Therapeutics Inc
Publication of IL325355A publication Critical patent/IL325355A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
IL325355A 2023-06-30 2024-06-28 RNA inhibitor targeting huntingtin expression IL325355A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363511187P 2023-06-30 2023-06-30
US202363591868P 2023-10-20 2023-10-20
US202463557370P 2024-02-23 2024-02-23
US202463654508P 2024-05-31 2024-05-31
PCT/US2024/036090 WO2025006937A2 (en) 2023-06-30 2024-06-28 Inhibitory rna targeting huntingtin expression

Publications (1)

Publication Number Publication Date
IL325355A true IL325355A (en) 2026-02-01

Family

ID=93940054

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325355A IL325355A (en) 2023-06-30 2024-06-28 RNA inhibitor targeting huntingtin expression

Country Status (8)

Country Link
EP (1) EP4735604A2 (de)
KR (1) KR20260051037A (de)
AU (1) AU2024307975A1 (de)
CO (1) CO2026000936A2 (de)
IL (1) IL325355A (de)
MX (1) MX2025014836A (de)
TW (1) TW202517782A (de)
WO (1) WO2025006937A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7009356B2 (ja) * 2015-04-03 2022-01-25 ユニバーシティ・オブ・マサチューセッツ ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物

Also Published As

Publication number Publication date
WO2025006937A2 (en) 2025-01-02
TW202517782A (zh) 2025-05-01
EP4735604A2 (de) 2026-05-06
KR20260051037A (ko) 2026-04-15
AU2024307975A1 (en) 2026-01-15
WO2025006937A9 (en) 2025-08-21
MX2025014836A (es) 2026-04-01
WO2025006937A3 (en) 2025-04-24
CO2026000936A2 (es) 2026-04-16

Similar Documents

Publication Publication Date Title
US12263227B2 (en) Optimized mRNA encoding CAS9 for use in LNPs
CA2952289C (en) Antisense oligonucleotides for the treatment of type 2 Usher syndrome
JP2021533805A (ja) 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法
US20240301380A1 (en) Compositions and Methods for Treating Fabry Disease
AU2022214192A9 (en) Compositions and methods for treating hereditary angioedema
JP2025172742A (ja) トランスサイレチン遺伝子における認識配列に対する特異性を有する操作されたメガヌクレアーゼ
IL323136A (en) Gene Healing ppt1
EP4601711A1 (de) Apoe gentherapie
EP4735604A2 (de) Auf die expression von huntingtin abzielende inhibitorische rna
JP2024517655A (ja) ヒトのミトコンドリアゲノムを標的とする操作されたメガヌクレアーゼ
AU2024363678A1 (en) Inhibitory nucleic acid targeting alpha synuclein expression
EP4720291A1 (de) Verfahren zur in-vivo-lenkung von lipidnanopartikeln